Who Will Enroll? Predicting Participation in a Phase II AIDS Vaccine Trial
Authors:
- Scott D. HalpernSHScott D. Halpern
- David S. MetzgerDMDavid S. Metzger
- Jesse A. BerlinJBJesse A. Berlin
- Peter A. UbelPUPeter A. Ubel
- 1 July 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 27 (3) , 281-288
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?The Lancet, 2000
- What Makes Clinical Research Ethical?JAMA, 2000
- Assessment of the Changing Willingness to Participate in Phase III HIV Vaccine Trials Among Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Willingness to Participate in HIV-1 Vaccine Efficacy Trials and the Effect of Media Events Among Gay and Bisexual Men in New York CityJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.Journal of Clinical Oncology, 1994
- Recruitment experience in clinical trials: Literature summary and annotated bibliographyControlled Clinical Trials, 1987
- Randomization Designs in Comparative Clinical TrialsNew England Journal of Medicine, 1984
- Some adaptive strategies for inadequate sample acquisition in veterans administration cooperative clinical trialsControlled Clinical Trials, 1980
- Statistics and ethics in medical research: III How large a sample?BMJ, 1980
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978